[go: up one dir, main page]

SK281785B6 - Uhľohydrátmi modifikované cytostatiká, liečivá s ich obsahom a ich použitie - Google Patents

Uhľohydrátmi modifikované cytostatiká, liečivá s ich obsahom a ich použitie Download PDF

Info

Publication number
SK281785B6
SK281785B6 SK1345-97A SK134597A SK281785B6 SK 281785 B6 SK281785 B6 SK 281785B6 SK 134597 A SK134597 A SK 134597A SK 281785 B6 SK281785 B6 SK 281785B6
Authority
SK
Slovakia
Prior art keywords
group
methanol
mmol
tlc
dichloromethane
Prior art date
Application number
SK1345-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK134597A3 (en
Inventor
Hans-Georg Lerchen
Dem Bruch Karsten Von
Uwe Petersen
J�Rg Baumgarten
Norbert Piel
Horst-Peter Antonicek
Walter Weichel
Michael Sperzel
Klaus-Dieter Bremm
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of SK134597A3 publication Critical patent/SK134597A3/sk
Publication of SK281785B6 publication Critical patent/SK281785B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
SK1345-97A 1995-04-04 1996-03-22 Uhľohydrátmi modifikované cytostatiká, liečivá s ich obsahom a ich použitie SK281785B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19512484A DE19512484A1 (de) 1995-04-04 1995-04-04 Kohlenhydratmodifizierte Cytostatika
PCT/EP1996/001279 WO1996031532A1 (fr) 1995-04-04 1996-03-22 Cytostatiques modifies aux glucides

Publications (2)

Publication Number Publication Date
SK134597A3 SK134597A3 (en) 1998-05-06
SK281785B6 true SK281785B6 (sk) 2001-07-10

Family

ID=7758679

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1345-97A SK281785B6 (sk) 1995-04-04 1996-03-22 Uhľohydrátmi modifikované cytostatiká, liečivá s ich obsahom a ich použitie

Country Status (27)

Country Link
US (1) US6271342B1 (fr)
EP (1) EP0819135B1 (fr)
JP (1) JPH11502860A (fr)
KR (1) KR19980703591A (fr)
CN (1) CN1185786A (fr)
AT (1) ATE186738T1 (fr)
AU (1) AU713466B2 (fr)
BG (1) BG63048B1 (fr)
BR (1) BR9604825A (fr)
CA (1) CA2217164A1 (fr)
CZ (1) CZ291098B6 (fr)
DE (2) DE19512484A1 (fr)
DK (1) DK0819135T3 (fr)
EE (1) EE03619B1 (fr)
ES (1) ES2140078T3 (fr)
GR (1) GR3032605T3 (fr)
HU (1) HUP9800513A3 (fr)
IS (1) IS1822B (fr)
MX (1) MX9707613A (fr)
NO (1) NO974564L (fr)
NZ (1) NZ305855A (fr)
PL (1) PL183574B1 (fr)
RU (1) RU2170234C2 (fr)
SK (1) SK281785B6 (fr)
TW (1) TW384290B (fr)
UA (1) UA61054C2 (fr)
WO (1) WO1996031532A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492335B1 (en) * 1996-09-30 2002-12-10 Bayer Aktiengesellschaft Glycoconjugates from modified camptothecin derivatives (20-O-linkage)
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
JP3101710B2 (ja) 1997-02-28 2000-10-23 工業技術院長 硫酸化オリゴ糖化合物
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
RU2193558C2 (ru) 1997-09-15 2002-11-27 Дзе Проктер Энд Гэмбл Компани Производные хинолона и фармацевтическая композиция на их основе
US6387928B1 (en) 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US7220824B1 (en) * 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
EP1219634A1 (fr) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Glycoconjugués d'agents cytostatiques avec lien peptidique spécifiquement clivable
EP1238678A1 (fr) * 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Conjugués d'agents cytostatiques et de ligands d'intégrine activés par des enzymes
AU2002350650A1 (en) * 2001-11-09 2003-05-19 Bayer Aktiengesellschaft Isotopically coded affinity marker 2
US7199149B2 (en) * 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
CN1922210A (zh) 2003-12-19 2007-02-28 健泰科生物技术公司 可用作治疗剂的单价抗体片段
BRPI0709209A2 (pt) 2006-03-28 2011-06-28 Procter & Gamble processo de redução de hidreto para preparo de intermediários de quinolona
US7456279B2 (en) 2006-03-28 2008-11-25 The Procter & Gamble Company Coupling process for preparing quinolone intermediates
DK2001862T3 (da) 2006-03-28 2011-08-08 Warner Chilcott Co Llc Malatsalte og polymorfe af (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyklopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolincarboxylsyre
CA2972635A1 (fr) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Mimetiques de lipide a, procedes de preparation, et leurs utilisations
SI3380124T1 (sl) 2015-11-25 2024-10-30 Legochem Biosciences, Inc. Konjugati, ki obsegajo samožrtvujoče skupine in z njimi povezani postopki
US11173214B2 (en) 2015-11-25 2021-11-16 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
AU2018246806B2 (en) 2017-03-29 2022-05-12 Ligachem Biosciences Inc. Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof
EP3790591A4 (fr) 2018-05-09 2022-05-11 LegoChem Biosciences, Inc. Compositions et méthodes associées à des conjugués anticorps-médicaments anti-cd19
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
JP2024537169A (ja) * 2021-10-06 2024-10-10 サムヤン コーポレイション 飽和フロジオキシン誘導体化合物及びその二次電池用添加剤としての使用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5977356A (ja) * 1982-06-30 1984-05-02 Fuji Photo Film Co Ltd 螢光アツセイ用多層分析要素およびそれを用いる螢光アツセイ法
DE3611194A1 (de) 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
EP0284071B1 (fr) * 1987-03-26 1994-06-08 Neorx Corporation Protéines et glycoprotéines marquées par des radionuclides de métal pour le diagnostic et la thérapie
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4980343A (en) * 1988-10-27 1990-12-25 Bayer Aktiengesellschaft Aminooxodihydroisoindoloquinazoline carcinostatic agents
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
CA2031803C (fr) * 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Derives de glycopeptides
US5160727A (en) * 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
US6075121A (en) 1990-05-15 2000-06-13 Chiron Corporation Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
US5420297A (en) 1990-10-24 1995-05-30 Fujisawa Pharmaceutical Co., Ltd. Peptides having substance P antagonistic activity
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DE4106101A1 (de) * 1991-02-27 1992-09-03 Bayer Ag Fucose-markierte cytostatika
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4120646A1 (de) * 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
DK0545198T3 (da) 1991-11-29 2000-03-20 Hoechst Ag Peptider med insulinagtig virkning
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
ZA935697B (en) 1992-08-07 1994-03-10 Sankyo Co Peptides capable of inhibiting the activity of hiv protease their preparation and their therapeutic use
US5872207A (en) 1992-09-04 1999-02-16 Sanofi Pharmaceuticals, Inc. N-terminal-marked peptides immobilized on glass beads and method of preparation and method of use thereof
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5576298A (en) 1992-11-30 1996-11-19 Research And Development Institute, Inc. At Montana State University Peptides from pseudomonas syringae possessing broad-spectrum antibiotic activity
SE9300012D0 (sv) 1993-01-05 1993-01-05 Astra Ab New peptides
US5750648A (en) 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
EP0647450A1 (fr) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Prodrogues améliorées pour activation médiée par enzyme
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
CA2173990A1 (fr) * 1993-10-12 1995-04-20 Narasinga Rao Banque de glyco-peptides permettant d'identifier des inhibiteurs d'adherence intercellulaire
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
FR2729668A1 (fr) 1995-01-23 1996-07-26 Adir Nouveaux derives de mercaptoalcanoyldipeptides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5677286A (en) * 1995-04-27 1997-10-14 The University Of Michigan Glycosylated analogs of camptothecin
US6143931A (en) 1997-04-16 2000-11-07 Arqule, Inc. Synthesis and use of α-ketoamide derivatives and arrays

Also Published As

Publication number Publication date
BR9604825A (pt) 1999-01-05
AU5397696A (en) 1996-10-23
AU713466B2 (en) 1999-12-02
PL322681A1 (en) 1998-02-16
DK0819135T3 (da) 2000-05-08
NO974564L (no) 1997-11-25
CN1185786A (zh) 1998-06-24
IS1822B (is) 2002-10-01
CA2217164A1 (fr) 1996-10-10
UA61054C2 (en) 2003-11-17
IS4562A (is) 1997-09-18
HUP9800513A2 (hu) 1998-06-29
WO1996031532A1 (fr) 1996-10-10
DE19512484A1 (de) 1996-10-17
EE03619B1 (et) 2002-02-15
BG101892A (en) 1998-05-29
NZ305855A (en) 1999-11-29
EP0819135B1 (fr) 1999-11-17
GR3032605T3 (en) 2000-05-31
TW384290B (en) 2000-03-11
PL183574B1 (pl) 2002-06-28
MX9707613A (es) 1997-12-31
EE9700258A (et) 1998-04-15
CZ291098B6 (cs) 2002-12-11
BG63048B1 (bg) 2001-02-28
US6271342B1 (en) 2001-08-07
KR19980703591A (ko) 1998-11-05
SK134597A3 (en) 1998-05-06
ATE186738T1 (de) 1999-12-15
HUP9800513A3 (en) 1998-09-28
CZ314397A3 (cs) 1998-01-14
JPH11502860A (ja) 1999-03-09
NO974564D0 (no) 1997-10-02
EP0819135A1 (fr) 1998-01-21
DE59603678D1 (de) 1999-12-23
ES2140078T3 (es) 2000-02-16
RU2170234C2 (ru) 2001-07-10

Similar Documents

Publication Publication Date Title
SK281785B6 (sk) Uhľohydrátmi modifikované cytostatiká, liečivá s ich obsahom a ich použitie
EP4356973A2 (fr) Dérivés de 6-(4-amino-3-méthyl-2-oxa-8-azaspiro[4.5!décan-8-yl)-3-(2,3-dichlorophényl)-2-méthylpyrimidin-4(3h)-one et composés apparentés en tant qu'inhibiteurs de ptpn11 (shp2)
EP1447099B1 (fr) Conjugués polyéthyléniques à activité antinéoplastique de composés cytostatiques et compositions pharmaceutiques les comprenant
EP3152223B1 (fr) Conjugué de mitomycine
DE102009051799B4 (de) Bifunktionale Prodrugs und Drugs
SA93130351B1 (ar) مشتقات إندولبيرولوكربازول
DE69911935T3 (de) Granulatimide-derivate zur behandlung von krebs
KR20150027217A (ko) 항진균성 항생 암포테리신 b의 n-치환된 제2 세대 유도체, 및 이의 제조 및 응용 방법
CA3135740A1 (fr) Traitements du cancer ciblant des cellules souches cancereuses
CZ293825B6 (cs) ChinoxalinyŹ způsob jejich výroby a jejich použití a farmaceutické prostředky tyto látky obsahující
US8252942B2 (en) Substituted imidazoline compounds
EP1373494B1 (fr) Derives de succinimide et de maleimide et leur utilisation comme inhibiteurs catalytiques de la topoisomerase ii
Torrence et al. Synthesis and pharmacokinetics of a dihydropyridine chemical delivery system for the antiimmunodeficiency virus agent, dideoxycytidine
NO180194B (no) 6-[X-(2-hydroksyetyl)aminoalkylÅ-5,11-diokso-5,6-dihydro-11-H-indeno[1,2-cÅisokinoliner og anvendelse derav til fremstilling av medikamenter, samt medikament inneholdende slike kinoliner
DE69624236T2 (de) Ausgewählte lösliche ester von indolcarbazolen die hydroxyl enthalten
AU7304096A (en) Novel amine derivatives of epipodophyllotoxin 2", 3"-dideoxyglycosides, preparation method therefor and use thereof as a drug and for treating cancer
DE10005275A1 (de) Neuartige Glycokonjugate
IL119334A (en) Carbohydrate modified cytostatics and medicaments containing them
HRP960440A2 (en) Sugar-modified cytostatics
DE10005275A9 (de) Neuartige glycokonjugate
KR102162351B1 (ko) 약물-결합 화합물 및 이의 용도
US20040214789A1 (en) Therapeutics
WO1996031518A1 (fr) Nouveaux derives bisindoliques inhibant les tumeurs et presentant un effet de liberation de calmoduline, et composition pharmaceutique les contenant